MS Patients had an increased proportion of MOG-specific CD8+ T cells, MOG-specific CD8+ TCM (HLA-A*03:01/MOG46-55 pentamers+CCR7+CD45RA−), MOG-specific CD8+ TEM (HLA-A*03:01/MOG46-55 pentamers+CCR7−CD45RA−), and MOG-specific CD8+ TEMRA (HLA-A*03:01/MOG46-55 pentamers+CCR7−CD45RA+) compared to OND patients and HC via FACScan (Figure 1). This evidence concerns the gene CD8A and myeloid sarcoma.